

1           **Genome-wide insights into the shared genetic landscape between metabolic**  
2           **dysfunction-associated fatty liver disease and cardiovascular diseases**

3   Jun Qiao<sup>1,2,9</sup>, Miaoran Chen<sup>3,9</sup>, Minjing Chang<sup>4,9</sup>, Wenjia Xie<sup>3</sup>, Wenqi Ma<sup>3</sup>, Tongtong  
4   Yang<sup>3</sup>, Qianru Zhao<sup>3</sup>, Kaixin Yao<sup>3</sup>, Xichen Yang<sup>3</sup>, Quan Yun<sup>3</sup>, Jing Xiao<sup>2,5</sup>, Xu He<sup>2,5</sup>,  
5   Wen Su<sup>6\*</sup>, Tao Xu<sup>7,8\*</sup>, Yuliang Feng<sup>1,10\*</sup>, Meixiao Zhan<sup>2,5\*</sup>

6   <sup>1</sup> Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong  
7   Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern  
8   University of Science and Technology, Shenzhen, China.

9   <sup>2</sup> Guangzhou First People's Hospital, the Second Affiliated Hospital, School of  
10   Medicine, South China University of Technology, Guangzhou, China.

11   <sup>3</sup> Department of Nephrology, Shanxi Kidney Disease Institute, Second Hospital of  
12   Shanxi Medical University, Taiyuan, China.

13   <sup>4</sup> School of Public Health and Emergency Management, School of Medicine,  
14   Southern University of Science and Technology, Shenzhen, China.

15   <sup>5</sup> Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and  
16   Treatment, Zhuhai People's Hospital, Zhuhai Clinical Medical College of Jinan  
17   University, Zhuhai, China.

18   <sup>6</sup> Department of Pathophysiology, Shenzhen University Health Science Center,  
19   Shenzhen University, Shenzhen, China.

20   <sup>7</sup> Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui  
21   Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei,  
22   China.

23 <sup>8</sup> Institute for Liver Diseases of Anhui Medical University, Hefei, China.

24 <sup>9</sup>These authors contributed equally to this work.

25 <sup>10</sup>Lead Contact.

26

27 **\*Corresponding author:**

28 Meixiao Zhan MD, PhD

29 Professor

30 Guangzhou First People's Hospital, the Second Affiliated Hospital, School of

31 Medicine, South China University of Technology, Guangzhou, 510006, China.

32 Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and

33 Treatment, Zhuhai People's Hospital, Zhuhai Clinical Medical College of Jinan

34 University, Zhuhai, 510009, China.

35 Tel:+86-(020)81048319

36 Email: [zhanmeixiao@ext.jnu.edu.cn](mailto:zhanmeixiao@ext.jnu.edu.cn)

37

38 Yuliang Feng MD, PhD

39 Associate Professor

40 Department of Pharmacology, School of Medicine; Southern University of Science

41 and Technology, Shenzhen, Guangdong, 518055, China.

42 Tel:+86 (755)-88012564

43 Email: [fengyl@sustech.edu.cn](mailto:fengyl@sustech.edu.cn)

44

45 Tao Xu PhD

46 Professor

47 Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui

48 Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei,

49 230032, China.

50 Institute for Liver Diseases of Anhui Medical University, Hefei, 230032, China.

51 Tel: +86 (0551)-65172131

52 Email: [xutao@ahmu.edu.cn](mailto:xutao@ahmu.edu.cn)

53

54 Wen Su MD, PhD

55 Associate Professor

56 Department of Pathophysiology, Shenzhen University Health Science Center,

57 Shenzhen University, Shenzhen, 518071, China.

58 Tel:+86 18188610625

59 Email: [suwen@szu.edu.cn](mailto:suwen@szu.edu.cn)

60

61 **Keywords:** Metabolic dysfunction-Associated fatty liver disease, Cardiovascular  
62 diseases, genome-wide association studies, Shared genetic architectures, Genetic  
63 pleiotropy.

64

65 Abstract: 275 words

66 Electronic word count manuscript: 4,568 words

67 Main figures and tables: 4 main figures, 1 main tables

68 Supplementary material: 2

69

70 **Conflict of interest statement**

71 All authors declare no competing interests.

72

73 **Financial support statement**

74 This study was supported by the Natural Science Foundation of China Excellent  
75 Young Scientists Fund (Overseas) (Grant no. K241141101), Guangdong Basic and  
76 Applied Basic Research Foundation for Distinguished Young Scholars (Grant no.  
77 2024B1515020047), Shenzhen Pengcheng Peacock Plan, Shenzhen Basic Research  
78 General Projects of Shenzhen Science and Technology Innovation Commission (Grant  
79 no. JCYJ20230807093514029) (To Y.F.), Shenzhen University 2035 Program for  
80 Excellent Research 8690200000314, the Shenzhen Science and Technology Fund for  
81 Distinguished Young Scholars (RCYX20231211090127031) (to W. S.), National  
82 Natural Science Foundation of China (Grant no. 82230067, 82272103), the

83 Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and  
84 Treatment (Grant no. 2021B1212040004), and the Natural Science Foundation of  
85 Guangdong Province of China (Grant no. 2022B1515020010) (To M.Z.), Shenzhen  
86 Science and Technology Program (Grant No. GJHZ20240218111401002 to J.B.), and  
87 Center for Computational Science and Engineering at Southern University of Science  
88 and Technology. The funder had no role in the design, implementation, analysis,  
89 interpretation of the data, approval of the manuscript, and decision to submit the  
90 manuscript for publication.

91

#### 92 **Author contributions**

93 J.Q., M.C., M.C., Y.F., and M.Z. as conceptualization and supervised this project and  
94 wrote the manuscript. W.X., W.M., T.Y., Q.Z., and K.Y. performed the main analyses  
95 and wrote the manuscript. X.Y, Q.Y., J.X., and X.H. performed the statistical analysis  
96 and assisted with interpreting the results. W.S., T.X., Y.F., and M.Z. provided expertise  
97 in cardiovascular biology and GWAS summary statistics. All authors provided  
98 intellectual content and approved the final version of the manuscript.

99 **Abstract**

100 **Background& Aims** :Multiple epidemiological studies have suggested an association  
101 between Metabolic dysfunction-associated fatty liver disease (MAFLD) and  
102 cardiovascular diseases (CVDs). However, the genetic components that are shared  
103 between the two remain unclear.

104 **Methods:** This genome-wide pleiotropic association study integrated comprehensive  
105 genome-wide association studies (GWAS) summary data from publicly available  
106 sources within European populations. It employed a range of genetic approaches to  
107 analyze the shared genetic architectures between MAFLD and six CVDs: atrial  
108 fibrillation (AF), coronary artery disease (CAD), venous thromboembolism (VTE),  
109 heart failure (HF), peripheral artery disease (PAD), and stroke. Initially, we examined  
110 the genetic correlation and overlap between these conditions. Subsequently,  
111 Mendelian Randomization (MR) analysis was conducted to investigate potential  
112 causal relationships. Finally, we explored horizontal pleiotropy at the levels of single  
113 nucleotide polymorphisms (SNPs), genes, and biological pathways to further  
114 elucidate the shared genetic mechanisms underlying.

115 **Results:** We observed significant genetic associations between MAFLD and four  
116 CVDs, including CAD, HF, PAD, and VTE. However, we noted extensive genetic  
117 overlap in all but MAFLD-AF. MR analysis established causal relationships from  
118 MAFLD to both AF and PAD. Regarding horizontal pleiotropy, 49 pleiotropic loci  
119 were identified at the SNP level with functional annotations, 13 demonstrating strong  
120 evidence of colocalization. At the gene level, 14 unique pleiotropic genes were found ,

121 with SAMM50 (located at 22q13.31) being particularly notable. Further pathway  
122 enrichment analysis indicated that these genes significantly contribute to the pathway  
123 of establishment of protein localization to membrane, highlighting their pivotal role in  
124 the pathophysiology of both MAFLD and CVD.

125 **Conclusions** : In all, our research proved the shared genetic architectures and  
126 mechanisms between MAFLD and CVD and elucidated their shared genetic etiology  
127 and biological mechanisms.


128

### 129 **Impact and implications**

130 Metabolic dysfunction-associated fatty liver disease (MAFLD) has reached a  
131 prevalence of 25-30% worldwide and has emerged as a global leading cause of  
132 liver-related morbidity and mortality. Studies have shown that people with MAFLD  
133 have a higher risk of cardiovascular disease (CVD) than the general population and  
134 there is currently no effective drug to treat the comorbidity of the two, which imposes  
135 a burden on the socioeconomic situation and the adverse effects are still rising.  
136 Therefore, it is critical to understand how MAFLD affects CVD. Our study provides  
137 unique insights into the mechanisms of comorbidity between MAFLD and CVD. The  
138 increasing number of complications has prompted us to explore new treatment options,  
139 so our study has important clinical significance.

140

### 141 **Graphical abstract**



142

143

144 **Highlights:**

- 145 ● The first comprehensive and systematic study to explore the common genetic
- 146 components between MAFLD and CVD.
- 147 ● MAFLD and CVDs share genetic architectures and mechanisms.
- 148 ● Genetically predicted MAFLD increases the risk of AF and PAD.
- 149 ● The effects of *SAMM50* (located at 22q13.31) on lipid metabolism support the
- 150 comorbidity of MAFLD and CVDs.
- 151 ● The localization of lipid droplet related contact site proteins to the membrane
- 152 plays a key role in the comorbidity of MAFLD and CVD.



153 **Introduction**

154 Non-alcoholic fatty liver disease (NAFLD) encompasses a range of liver disorders,  
155 from simple steatosis to non-alcoholic steatohepatitis, fibrosis, and cirrhosis, typically  
156 arising without significant alcohol consumption. According to a recent consensus  
157 statement by an international panel of experts, Metabolic dysfunction-Associated fatty  
158 liver disease (MAFLD) has been proposed as a more appropriate and comprehensive  
159 term to replace NAFLD, better reflecting its association with known metabolic  
160 dysfunctions<sup>1,2</sup>. MAFLD has emerged as a global leading cause of liver-related  
161 morbidity and mortality<sup>3</sup>. While liver-related complications significantly elevate  
162 mortality rates, cardiovascular diseases (CVDs) remain the primary cause of death in  
163 patients with MAFLD<sup>4</sup>. Clinically, individuals with MAFLD often exhibit elevated  
164 triglyceride levels and an increased concentration of residual lipoprotein particles,  
165 thereby elevating their risk for CVDs<sup>5</sup>. Lipoproteins containing apolipoprotein C3  
166 (ApoC3) have been shown to activate the IL(interleukin)-1 to IL-6 to CRP  
167 (C-Reactive Protein) inflammatory pathway, which is implicated in the development  
168 of coronary artery disease (CAD), venous thromboembolism (VTE), Stroke, and  
169 vascular inflammation<sup>6</sup>. A meta-analysis of 16 observational studies, encompassing  
170 34,043 patients over a median follow-up of 6.9 years, reported a 64% increased risk  
171 of fatal and/or non-fatal CVD events in patients with MAFLD compared to those  
172 without<sup>7</sup>. The strong epidemiological evidence underscores the association between  
173 MAFLD and an escalated risk of CVDs, which might suggest increased genetic  
174 liability to CVD in subgroups of patients with MAFLD.

175

176 Enhanced comprehension of the shared genetic foundations between MAFLD and  
177 various CVDs could offer valuable insights into these conditions. Recent large-scale  
178 genome-wide association studies (GWAS) have uncovered numerous risk loci linked  
179 to both MAFLD and CVDs, identifying several shared risk loci, notably at 19p13.11  
180 (*TM6SF2*)<sup>8</sup> and 22q13.31 (*PNPLA3*)<sup>9</sup>. Increasing evidence suggests genetic overlap  
181 between MAFLD and CVDs. For instance, recent data suggested weak to moderate  
182 positive genetic correlations between MAFLD and CAD, heart failure (HF), and  
183 Hypertension, a major risk factor for CVDs<sup>10</sup>. Genetic correlation provides a  
184 summary measure of the correlation across all single-nucleotide polymorphism (SNP)  
185 effect sizes. However, it cannot differentiate between genetic overlap with a  
186 combination of concordant and discordant effects and a complete absence of genetic  
187 overlap, frequently resulting in an estimate close to 0 in both scenarios<sup>11</sup>. While  
188 genetic correlation can provide evidence for overall genomic similarity between traits,  
189 it does not provide information for considering biological plausibility or inferring  
190 potential causal relationships<sup>12</sup>. Previous Mendelian randomization(MR) analyses  
191 investigating the link between MAFLD and CVDs have shown that the causal  
192 relationship was not consistently robust due to possible bias by the presence of  
193 horizontal pleiotropy or sample overlap<sup>13-15</sup>. Despite these insights, a significant  
194 portion of the genetic underpinnings of MAFLD and CVDs remain elusive. Moreover,  
195 individual loci associated with both conditions have not been systematically analyzed,  
196 an examination of which could clarify the impact of different risk loci on the

197 comorbidities of MAFLD and CVDs, as well as identify biological pathways offering  
198 therapeutic promise.

199

200 This study aims to uncover their genetic overlap beyond the genetic correlation  
201 between MAFLD and six major CVDs—atrial fibrillation (AF), CAD, VTE, HF,  
202 peripheral artery disease (PAD), and Stroke—by leveraging unprecedentedly large  
203 GWAS summary data from European ancestry. We applied the genetic analysis  
204 incorporating pleiotropy and annotation (GPA), which estimates the total number of  
205 unique and shared genetic variants between pairs of traits. The relevance of mixed  
206 effects has been further emphasized by Local Analysis of [co]Variant Annotation  
207 (LAVA), which calculates local genetic correlations across the genome, even in the  
208 presence of minimal  $r_g$ . Given that GPA and LAVA quantify total genetic overlap but  
209 cannot pinpoint shared genomic loci, we subsequently utilized the Pleiotropic  
210 Analysis under a Composite Null Hypothesis (PLACO) method to discover loci  
211 jointly associated with MAFLD and each CVD beyond genome-wide significance, a  
212 critical step for gaining biological insights. Additionally, we also utilize Latent  
213 Heritable Confounder Mendelian randomization (LHC-MR) analyses to explore  
214 potential causal relationships between MAFLD and CVDs, considering sample  
215 overlap, bidirectional causal associations, and unobserved heritable confounders.  
216 Together, these methods augment the insights gained from genetic correlation  
217 analyses, shedding light on the distinct and common genetic frameworks  
218 underpinning MAFLD and CVDs, with implications for how we conceptualize

219 genetic risk for the comorbidity between MAFLD and CVDs.

220

## 221 **Materials and methods**

### 222 **Data sources and quality control**

223 Genetic associations with MAFLD were derived from the largest genome-wide  
224 meta-analysis to date, involving 8,434 cases and 770,180 controls from four European  
225 cohorts: the Electronic Medical Records and Genomics (eMERGE) Network, the UK  
226 Biobank (UKB), the Estonian Biobank (EstBB), and the FinnGen Consortium, of  
227 which the diagnosis was determined based on the electronic health records of all  
228 participants<sup>16</sup>. To ensure that the sample size is large enough to produce reliable  
229 results, we use GWAS summary data from studies with sample sizes greater than  
230 50,000. Accordingly, our study encompassed six major CVDs, including AF, CAD,  
231 VTE, HF, PAD, and Stroke. Specifically, GWAS summary statistics for AF were  
232 retrieved from a recent meta-analysis of six cohorts, including the Health Study  
233 Nord-Trøndelag (HUNT), deCODE, Michigan Genome Initiative (MGI), DiscovEHR,  
234 UKB, and AFGen consortium, comprising 60,620 cases and 970,216 controls of  
235 European ancestry<sup>17</sup>. GWAS summary statistics for CAD were extracted from a  
236 genome-wide meta-analysis by the CARDIoGRAMplusC4D and UKB consortium,  
237 including 181,522 cases and 984,168 controls of European ancestry<sup>18</sup>. GWAS  
238 summary statistics for VTE were collected from the largest meta-analysis of seven  
239 cohorts to date, including 81,190 cases and 1,419,671 controls of European ancestry<sup>19</sup>.  
240 GWAS summary data for HF were derived from the Heart Failure Molecular

241 Epidemiology for Therapeutic Targets (HERMES) consortium, entailing 47,309 cases  
242 and 930,014 controls<sup>20</sup>. GWAS summary data for PAD came from the largest  
243 meta-analysis conducted on data from 11 independent cohorts, totaling 12,086 cases  
244 and 499,548 controls<sup>21</sup>. GWAS summary data for Stroke were obtained from the  
245 GIGASTROKE consortium, which included 73,652 cases and 1,234,808 controls<sup>22</sup>.  
246 Detailed information about these GWAS summary data and their original publication  
247 sources is available in Supplementary Table 1.

248

249 Quality control was carried out strictly for GWAS summary data per the following  
250 steps before further analysis:(i) alignment with the hg19 genome assembly, and the  
251 1000 Genomes Project v3 Europeans was used as the reference<sup>23</sup>; (ii) only including  
252 autosomal SNPs; (iii) SNPs with duplicate entries or missing rsIDs were eliminated;  
253 (iv) SNPs with a minor allele frequency (MAF) value of 0.01 or less were excluded.  
254 To ensure robust results, we normalized the GWAS summary data for all phenotypic  
255 SNPs, yielding 6,479,654 common SNPs across all diseases.

256

### 257 **Assessing the genetic correlates of MAFLD and CVDs**

258 We employed cross-trait linkage disequilibrium score regression (LDSC) analyses to  
259 assess the genetic correlation ( $r_g$ ) between MAFLD and six major CVDs<sup>24</sup>. LDSC, an  
260 effective method for evaluating genetic correlations across the genome, utilizes the  
261 linkage disequilibrium (LD) structure to estimate individual SNP effect sizes from  
262 GWAS summary statistics<sup>25</sup>. The method involves regression of these GWAS  
263 summary statistics against LD scores derived from the European 1000 Genomes  
264 Project, minimizing biases related to polygenicity, sample overlap, and population

265 stratification<sup>24</sup>. Due to its complexity, the major histocompatibility complex (MHC)  
266 region was excluded from our analysis. First, univariate LDSC was conducted to  
267 determine the SNP-based heritability ( $h^2_{SNP}$ ) for MAFLD and each CVD.  
268 Subsequently, bivariate LDSC estimated the  $r_g$  between MAFLD and CVDs by  
269 performing a weighted linear regression on the product of Z-scores for MAFLD and  
270 CVDs against the LD scores for all available genetic variants. This approach provides  
271 an unbiased estimate of  $r_g$  and reliably measures genetic correlations even in  
272 overlapping samples between GWAS datasets. Genetic correlations rang from -1 to +1,  
273 with values closer to the extremes indicating stronger influences, and negative values  
274 suggest opposite-direction effects, while positive values indicate the same direction.  
275 *P*-values below a Bonferroni-corrected significance threshold ( $P = 0.05 / 6 = 8.3 \times 10^{-3}$ )  
276 were considered statistically significant.

277

278 To identify tissues closely associated with genetic susceptibility SNPs for MAFLD  
279 and CVDs, we used LDSC applied to specifically expressed genes (LDSC-SEG)<sup>26</sup>.  
280 This method combines aggregate GWAS summary statistics with tissue-specific gene  
281 expression data for targeted tissue enrichment analysis<sup>26</sup>. Our analysis incorporated  
282 various gene sets, including multi-tissue gene expression data from the GTEx project  
283 (v8) and chromatin information from the Roadmap Epigenomics and ENCODE  
284 initiatives<sup>26,27</sup>. Using the baseline model and comprehensive gene sets, we prioritized  
285 genes from GTEx based on computed t-statistics, focusing on the top 10% of  
286 specifically expressed candidate genes that exhibited the highest t-statistics. The  
287 *P*-value from the regression coefficient's z-score was used to determine the  
288 significance coefficient, and a false discovery rate (FDR) of less than 0.05 was  
289 applied to assess the significance of enriched SNPs in specific tissues.

290

### 291 **Estimating genetic overlap between MAFLD and CVDs**

292 To address the "missing heritability" issue in complex traits, the Genetic Analysis  
293 incorporating Pleiotropy and Annotation (GPA) was specifically developed. This tool

294 was specifically designed to overcome the limitations posed by the small proportion  
295 of genetic variants identified through standard approaches that account for only a  
296 minimal part of the expected genetic contribution<sup>28</sup>. GPA achieves this by integrating  
297 diverse genomic data and annotation information, thereby enhancing the prioritization  
298 of GWAS results and providing a more comprehensive estimation of genetic overlap.  
299 Notably, in the absence of annotation data, GPA can infer genetic overlap using  
300 p-value interactions of the corresponding phenotypes<sup>28</sup>. GPA is based on key  
301 assumptions regarding p-value distributions: p-values from null SNPs are expected to  
302 adhere to a uniform distribution, reflecting no association, while p-values from  
303 non-null SNPs are presumed to follow a beta distribution, indicating potential  
304 associations. Within this framework, GPA categorizes SNPs into four groups based on  
305 their p-value characteristics:  $\pi_{00}$  suggests no association with either trait;  $\pi_{01}$  denotes  
306 an association exclusively with the first trait;  $\pi_{10}$  signifies an association solely with  
307 the second trait; and  $\pi_{11}$  represents an association with both traits. This classification  
308 can estimate  $\pi_{11} / (\pi_{10} + \pi_{11} + \pi_{11})$ , an important ratio indicator that represents the  
309 proportion of SNPs shared by two traits, suggesting the extent to which a common  
310 biological pathway may be shared between the two traits<sup>28</sup>. Subsequently, the  
311 likelihood ratio test (LRT) was used to assess the statistical significance of the  
312 observed genetic overlap<sup>28</sup>. Given the complex interrelations among SNPs, GPA  
313 estimates are susceptible to biases from LD. We used PLINK1.9 for LD pruning to  
314 address this, drawing on data from the 1000 Genomes Project Phase 3<sup>23</sup> for European  
315 ancestry. We also applied a Bonferroni-corrected significance threshold for multiple  
316 comparisons, set at  $P = 0.05 / \text{number of trait pairs} = 0.05 / 6 = 8.3 \times 10^{-3}$ .

317

### 318 **Calculating local genetic correlations between MAFLD and CVDs**

319 LAVA facilitates the assessment of local genetic correlations by partitioning the  
320 genome into smaller regions, which enables detailed insights into the influence of  
321 genetic variants on various traits at a regional level, rather than across the entire  
322 genome<sup>29</sup>. LAVA analyses genetic correlations within different genomic segments,

323 using the regions delineated by Werme et al. as autosomal LD blocks<sup>29</sup>, characterized  
324 by minimal connectivity between blocks. The genome was partitioned into 2,495  
325 semi-independent regions, each approximately 1 Mb, using genotype data from the  
326 1000 Genomes Project Phase 3 European ancestry as the LD reference panel and  
327 MHC region (chr 6: 25-35 Mb) was excluded. In conducting the genetic association  
328 study, we first performed a preliminary univariate analysis using LAVA to estimate the  
329 local heritability of MAFLD and CVDs. With this step, we could identify regions that  
330 showed significant signals in the local genetic analysis. We then performed bivariate  
331 LAVA analyses of these regions to explore regional genetic associations between  
332 MAFLD and CVDs. To ensure the statistical significance of the results, the FDR  
333 method was employed to calculate the adjusted p-value. FDR less than 0.05 was  
334 considered the genetic correlation of these regions to be statistically significant.

335

### 336 **Evaluate the causal relationship between MAFLD and CVDs**

337 The genome-wide and local genetic correlations provide insights into the shared  
338 genetic basis between trait pairs, but these correlations do not imply causality in either  
339 direction. To overcome these limitations, linkage disequilibrium heterogeneity causal  
340 Mendelian randomization (LHC-MR) provides a more refined approach to assess  
341 bidirectional causality while minimizing confounding effects<sup>30</sup>. This method extends  
342 traditional MR by addressing limitations of the standard two-sample MR approach,  
343 such as potential sample overlap, under-utilization of genome-wide markers, and the  
344 need to understand exposure-outcome relationships. LHC-MR assesses bidirectional  
345 causality by categorizing associations between exposure and outcome into four  
346 categories: (i) causal effect of exposure on outcome, (ii) causal effect of outcome on  
347 exposure, (iii) effect of confounders whose exposure affects the outcome process



348 (vertical pleiotropy), and (iv) effect of confounders whose exposure affects the  
349 outcome independently (horizontal pleiotropy<sup>30</sup>). Unlike traditional MR, LHC-MR  
350 utilizes all genome-wide genetic variation rather than only genome-wide significant  
351 variation<sup>30</sup>. To ensure the stability of the results, the Bonferroni correction  
352 significance threshold was set at  $4.17 \times 10^{-3}$  ( $P = 0.05/\text{number of trait pairs}/\text{number of}$   
353 tests). When  $P_{axy} < 4.17 \times 10^{-3}$  and  $P_{ayx} > 0.05$ , it suggests a one-way causal  
354 relationship from MAFLD to CVD; conversely, when  $P_{ayx} < 4.17 \times 10^{-3}$  and  $P_{axy} > 0.05$ ,  
355 it implies a one-way causal relationship from CVD to MAFLD. However, if both  $P_{axy}$   
356 and  $P_{ayx}$ , exceeding the significance threshold, it indicates bidirectional causality  
357 between MAFLD and CVD. We used traditional two-sample MR techniques for  
358 sensitivity analysis, including Inverse Variance Weighting (IVW), MR Egger,  
359 Weighted Median, Simple Mode, and Weighted Mode.  $P$ -values below the 0.05  
360 threshold were considered statistically significant.

361

### 362 **Identification of pleiotropic loci between MAFLD and CVDs**

363 To unravel the shared genetic mechanisms between MAFLD and six major CVDs, our  
364 study employs the PLACO, extending pleiotropic analysis to the SNP level<sup>31</sup>. PLACO  
365 utilizes the summary statistic from GWAS to calculate the test statistic for the product  
366 of the  $Z$ -statistics for each SNP in the two trait analyses. This calculation is based on  
367 the assumption of a mixed distribution, which allows for the assessment of SNP  
368 associations across traits. Using this assumption, PLACO can rigorously analyze  
369 individual SNPs by pairwise  $Z$ -statistics, categorizing the null hypothesis of

370 pleiotropy into three distinct and mutually exclusive scenarios: (i) H00, indicating no  
371 association of the SNP with either trait; (ii) H10, signifying an association with the  
372 first trait but not the second; and (iii) H01, representing an association with the second  
373 trait but not the first. The rejection of the composite null hypothesis, which  
374 encompasses all three scenarios, indicates horizontal pleiotropy, suggesting that the  
375 SNP influences both traits through identical mechanisms. We applied a stringent  
376 significance threshold of  $5 \times 10^{-8}$  to identify SNPs exhibiting statistically significant  
377 pleiotropy.

378

### 379 **Functional annotation based on pleiotropic loci**

380 To identify and conduct independent genomic loci between MAFLD and six major  
381 CVDs, we utilized the Functional Mapping and Annotation (FUMA) platform<sup>32</sup>.  
382 FUMA, an online tool designed to enhance the interpretability of GWAS findings,  
383 performs functional annotation of pleiotropic SNPs revealed by PLACO analysis.  
384 Lead SNPs are merged to delineate distinct genomic loci in LD blocks within 500 kb  
385 of lead SNPs by FUMA, utilizing default parameters and LD data from the 1000  
386 Genomes Project Phase 3 European cohort. Lead SNP was further selected by  $r^2 < 0.1$   
387 for minimal LD in independent significant SNPs (genome-wide significance  $P <$   
388  $5 \times 10^{-8}$  and  $r^2 < 0.6$ ), indicating higher independence from adjacent genetic variations.  
389 Despite these regions potentially containing several lead SNPs, the Top Lead SNP is  
390 identified with the lowest P-value within a given region. Locus was deemed novel to  
391 MAFLD and CVD if they did not coincide with the loci previously reported in the

392 original GWAS.

393

394 Functional annotations for Top Lead SNPs, provided by FUMA, include Combined  
395 Annotation-Dependent Depletion (CADD<sup>33</sup>) scores, regulatory function probability  
396 scores via RegulomeDB (RDB<sup>34</sup>), and potential effects on gene function as annotated  
397 by ANNOVAR<sup>35</sup>. CADD scores, which assess the harmful impact of SNPs, are  
398 utilized with a threshold: a score greater than 12.37 is considered likely to be harmful,  
399 reflecting the SNP's potential to affect biological functions adversely. RDB scores,  
400 ranging from 1 to 7, indicate the likelihood of an SNP being located in a regulatory  
401 function area, with lower scores denoting higher functional significance. Lead SNPs  
402 were annotated using ANNOVAR to evaluate their proximity to genes and potential  
403 impacts on gene functions, thus providing insights into how these variants might  
404 influence genetic pathways or disease mechanisms. For the identification of putative  
405 causal genes, SNPs were mapped using two approaches: positional mapping within a  
406 10-kb window around the SNP and eQTL mapping.

407

#### 408 **Colocalization analysis**

409 After annotating pleiotropic loci using FUMA, we analyzed colocalization with the  
410 "COLOC" R package to identify potential shared causal variants across trait pairs  
411 within each locus. COLOC analysis employs Bayes factors to evaluate the likelihood  
412 of shared causal variation between two sets of trait-associated loci, calculating  
413 posterior probabilities (PP) for five mutually exclusive hypotheses at each locus: (i)

414 no SNP is associated with either trait (H0); (ii) a causal SNP is associated only with  
415 the first trait (H1); (iii) a causal SNP is associated only with the second trait (H2); (iv)  
416 each trait is influenced by independent, distinct causal SNPs (H3); and (v) a single  
417 SNP acts as a causal variant for both traits (H4). Our analysis primarily focuses on  
418 hypothesis H4, which posits a shared causal variant for both traits. Strong evidence of  
419 colocalization at a genomic locus is indicated if the posterior probability for shared  
420 causal variants (PPH4) exceeds 0.70. The SNP with the highest PPH4 within these  
421 loci is identified as the candidate causal variant.

422

### 423 **Gene-level annotation analysis**

424 To pinpoint genes that exhibit pleiotropic effects within genomic loci, a Multi-marker  
425 Analysis of GenoMic Annotation (MAGMA) was performed based on the results of  
426 PLACO and individual GWAS<sup>36</sup>. MAGMA, a tool rooted in multivariable regression  
427 models, computes the significance of gene-trait associations by incorporating  
428 principal component analysis. It then employs the F-test to ascertain p-values for each  
429 gene, considering factors such as gene size, SNP count per gene, and LD among the  
430 markers. Consistency in gene-based testing was ensured by defining gene boundaries,  
431 which encompassed regions extending  $\pm 10$  kb from the termini of each gene. We  
432 obtained MAGMA gene IDs and location data for 17,636 protein-coding genes,  
433 aligning SNP locations with Human Gene Build 37 (GRCh37/hg19). The MHC  
434 region (chr6: 25-35 Mb) was excluded from MAGMA's gene-based analysis.  
435 Significant gene associations were identified using a stringent Bonferroni-corrected

436 threshold set at  $P = 4.73 \times 10^{-7}$  ( $0.05 / 17,636 / 6$ ), accounting for the number of  
437 protein-coding genes and trait pairs analyzed.

438

439 Recognizing that MAGMA links SNPs to genes based primarily on physical  
440 proximity, we extended our analysis to include the eQTL-informed MAGMA  
441 (e-MAGMA)<sup>37</sup>. The e-MAGMA utilizes tissue-specific eQTL data to assign risk  
442 variants to presumptive genes, thereby converting genome-wide association summary  
443 statistics into gene-specific metrics. This method leverages tissue-specific eQTL data  
444 from the GTEx project to account for long-range regulatory effects, enhancing the  
445 interpretation of GWAS association signals. MHC region (chr6: 25-35 Mb) was  
446 excluded in e-MAGMA analysis results as well as MAGMA to avoid confounding  
447 due to complex LD patterns. Our study utilizes the GTEx v8 comprehensive database  
448 containing eQTL data from 47 different tissues, based on PLACO results, to delve  
449 into gene-disease associations at a fine-grained tissue level, and to gain a more  
450 detailed understanding of the tissue-specific genetic architecture behind the relevant  
451 diseases. To minimize confounding factors associated with broad tissue analyses, we  
452 refined our approach by selecting a subset of tissues based on insights from  
453 LDSC-SEG results and previous research. Specifically, our focused analysis included  
454 ten tissues: two types of adipose tissue (subcutaneous and visceral omental fat), three  
455 arterial tissues (aorta, coronary, and tibial arteries), two cardiac tissues (left ventricle  
456 and atrial appendage), as well as liver, EBV-transformed lymphocytes, and whole  
457 blood. Using the 1000 Genomes Project v3 European samples as the LD reference, we

458 calculated tissue-specific p-values for each gene across the selected tissues. We  
459 applied a Bonferroni correction to determine the significance of these p-values,  
460 accounting for the number of tissue-specific protein-coding genes and trait pairs  
461 examined. For instance, the significance threshold for adipose subcutaneous tissue  
462 was set at  $P = 0.05 / 7,560 / 6 = 1.10 \times 10^{-6}$ .

463

464 To further explore tissue-specific gene-trait associations for MAFLD and CVDs, we  
465 conducted a transcriptome-wide association study (TWAS) using single-trait GWAS  
466 results<sup>38</sup>. Employing the FUSION framework, TWAS integrates GWAS summary  
467 statistics with eQTL data from the GTEx v8 dataset to assess how variations in gene  
468 expression across specific tissues influence phenotypes. We used pre-computed gene  
469 expression weight references from the tissues analyzed in our e-MAGMA study. LD  
470 pruning was performed during the third phase of the 1000 Genomes Project using the  
471 LD structures of the European subpopulation. Significance thresholds were adjusted  
472 using tissue-specific Bonferroni corrections to control for multiple tests.

473

#### 474 **Pathway level analyses**

475 We performed functional enrichment analysis on the overlapped gene lists  
476 significantly identified by MAGMA and e-MAGMA analyses using the ToppGene  
477 functional annotation tool (ToppFun)<sup>39</sup>. ToppGene Suite is a comprehensive portal for  
478 gene list enrichment analysis and candidate gene prioritization. The ToppFun  
479 application provides a variety of annotation data types, including transcriptome,

480 proteome, regulatory elements (such as transcription factor binding sites (TFBS) and  
481 microRNA), ontologies (such as GO and Pathway), phenotypes (including human  
482 diseases and mouse phenotypes), pharmacometrics (drug-gene associations), and  
483 literature co-citations. Additionally, ToppFun prioritizes candidate genes based on  
484 their functional similarity to ensure rigorous and thorough analysis. Significant GO  
485 terms were identified with an FDR threshold of 0.05.

486

## 487 **Results**

### 488 **SNP-based heritability and genetic correlations between MAFLD and CVDs**

489 After harmonizing and filtering SNPs common across GWAS summary statistics,  
490 LDSC was utilized to estimate the  $h^2_{SNP}$  and the genome-wide genetic correlations ( $r_g$ )  
491 between MAFLD and CVDs. Univariate LDSC analysis indicated that the  $h^2_{SNP}$  of  
492 MAFLD was 0.002 (SE = 0.001). In comparison, the  $h^2_{SNP}$  of CVDs ranged from  
493 0.008 to 0.032, with CAD exhibiting the highest heritability ( $h^2_{SNP} = 0.032$ , SE =  
494  $1.90 \times 10^{-3}$ ) and HF the lowest ( $h^2_{SNP} = 0.008$ , SE =  $3.01 \times 10^{-3}$ ). Notably, the  
495 heritability of MAFLD was lower than that of any individual CVD. Bivariate LDSC  
496 revealed that all trait pairs exhibited positive genetic correlations under a relaxed  
497 significance threshold ( $P < 0.05$ ). However, four trait pairs maintained statistical  
498 significance after applying a Bonferroni correction for multiple comparisons ( $P <$   
499  $0.05 / 6 = 8.33 \times 10^{-3}$ ). These findings highlight the subtle genetic interactions between  
500 MAFLD and CVD, which underscores the potential for shared genetic pathways to  
501 influence these complex diseases.

502

503 **Genetic overlap analysis**

504 The  $r_g$  is a vital metric that reflects the genetic relationship between trait pairs,  
505 providing insights into their shared genetic architecture. Importantly, a  $r_g$  value close  
506 to zero does not necessarily signify the absence of a genetic association between traits.  
507 This apparent discrepancy can arise from various factors, such as the mixed effects of  
508 homozygosity and reverse effects, or a lack of genetic overlap, which may mask the  
509 true genetic relationships and lead to misleadingly low  $r_g$  values. Recognizing this  
510 limitation highlights a "missing dimension" in our understanding of genetic  
511 connections between phenotypes. To enhance our understanding of genetic  
512 interactions and address these challenges, advanced statistical methods, including  
513 GPA and LAVA, have been employed by us.

514

515 The intricacies of the genetic relationships observed between MAFLD and CVDs,  
516 particularly the surprising contrast between significant genetic overlap and weak  
517 correlation in some cases, underscore the complexity of genetic interactions and the  
518 importance of considering additional analytical dimensions. In our analysis of six trait  
519 pairs, the MAFLD-AF pair was the only one that failed to meet the Bonferroni  
520 correction threshold, indicating a lack of significant genetic overlap. Conversely, the  
521 MAFLD-CAD pair demonstrated the most significant genetic overlap, evidenced by a  
522 P-value of  $7.12 \times 10^{-31}$ , aligning with LDSC results, which revealed the highest genetic  
523 correlation ( $r_g = 0.627$ ,  $P = 5.18 \times 10^{-6}$ ). Although a significant genetic overlap was



524 identified between MAFLD and Stroke ( $P = 6.96 \times 10^{-6}$ ), the minimal PAR value (PAR  
525  $= 7.00 \times 10^{-4}$ ) highlights a small proportion of pleiotropic SNPs. Furthermore, the weak  
526 genetic correlation between MAFLD and Stroke ( $r_g = 0.627$ ,  $P = 3.98 \times 10^{-2}$ ) suggests  
527 that the presence of multiple closely linked SNPs with independent or heterogeneous  
528 impacts may obscure consistent effects, resulting in a correlation that falls short of  
529 higher statistical confidence thresholds. This phenomenon, where broad genetic  
530 overlap coexists with weak genetic correlation, implies that mixed effects may mask  
531 the true genome-wide genetic correlation.

532

### 533 **Regional genetic correlation analysis**

534 LAVA evaluates genetic correlations within specific genomic regions and identifies  
535 subtle genetic effects that might elude detection by LDSC. This capability is vital, as  
536 genetic influences often vary across the genome, and the correlations between traits  
537 can differ markedly by region. First, a univariate LAVA analysis was conducted by us  
538 with a strict threshold of  $P < 1 \times 10^{-4}$  to identify regions with strong genetic signals,  
539 resulting in the identification of 2,336 significant regions. These regions were then  
540 formed into 77 bivariate test sets for more detailed analysis. In the subsequent  
541 bivariate LAVA analysis, we applied a looser significance threshold ( $P < 0.05$ ),  
542 identifying approximately 22 genomic regions showing genetic signals associated  
543 with all trait pairs. Notably, our LAVA analysis revealed five key genetic regions  
544 associated with MAFLD and stroke, including three negatively and two positively  
545 correlated regions. This discovery of substantial genetic overlap starkly contrasts the

546 lack of significant genome-wide associations found using LDSC. This discrepancy  
547 between the LAVA and LDSC results underscores the complex genetic architecture,  
548 suggesting that regions with both positive and negative correlations may lead to a  
549 heterogeneous distribution of genetic effects. Such complexity might mask genetic  
550 signals when assessed on a genome-wide scale using LDSC. We then applied a  
551 stricter threshold of  $P < 6.49 \times 10^{-4}$  to account for multiple comparisons. This led to  
552 the identification of a significant region on chromosome 8, spanning from  
553 125,453,321 to 126,766,827, showing a strong correlation between MAFLD and CAD  
554 ( $r_g = 0.509$ ,  $P = 3.05 \times 10^{-6}$ ), aligns with the positive genetic correlation observed across  
555 the genome by LDSC.

556

### 557 **Causal relationship linking MAFLD and CVDs**

558 The observed genetic overlap between MAFLD and CVDs extends beyond mere  
559 correlation, suggesting the presence of pleiotropy. However, determining whether this  
560 pleiotropy is horizontal or vertical remains unresolved. To clarify this, we utilized the  
561 LHC-MR approach, which sheds light on the bidirectional causal relationships  
562 between MAFLD and CVD through vertical pleiotropy. Our findings revealed a  
563 significant positive causal effect of MAFLD on both AF and PAD, with odds ratios  
564 (OR) of 1.11 ( $P = 2.36 \times 10^{-3}$ ) and 1.375 ( $P = 1.39 \times 10^{-4}$ ), respectively. These results  
565 underscore MAFLD as a critical risk factor in the onset and development of both AF  
566 and PAD, aligning with previous research that highlights MAFLD's role in increasing  
567 the prevalence of these disorders. Notably, we found no evidence to suggest reverse

568 causality in these relationships.

569

### 570 **Shared variants and functional annotation of MAFLDs and CVDs**

571 To further dissect the complex genetic mechanisms between MAFLD and CVDs, we  
572 utilized PLACO to identify significant pleiotropic variants indicative of horizontal  
573 pleiotropy. This inquiry, through its meticulous analysis, unveiled a trove of 3,438  
574 SNPs exhibiting significant pleiotropic influences. Subsequently, these SNPs  
575 underwent a process of annotation, facilitated by the FUMA tool, which meticulously  
576 delineated 49 distinct loci spanning 20 chromosomal regions, enriching our  
577 understanding of the genetic landscape under scrutiny. Seven of the 49 loci identified  
578 were novel and had not been previously associated with MAFLD or CVDs. Among  
579 the 22 loci (44.9%), the selected effect alleles at the top SNPs within or near loci  
580 demonstrated effect directions that were consistent with each other which means they  
581 may concurrently increase ADs and CVDs or diminish the risk of developing ADs and  
582 CVDs. Notably, three loci, 22q13.31, 16q12.2, and 8q24.13, were associated with  
583 more than half of the trait pairs analyzed. The chromosomal region 22q13.31, in  
584 particular, is implicated in five trait pairs, excluding MAFLD-Stroke, highlighting its  
585 significance in the pleiotropic landscape. For example, *SAMM50* located at 22q13.31,  
586 studies have shown that *SAMM50* gene polymorphisms are associated with the  
587 occurrence and severity of fatty liver disease, which may be related to reduced fatty  
588 acid oxidation caused by *SAMM50* deficiency<sup>40</sup>. Although there is no direct evidence  
589 linking *SAMM50* to cardiovascular disease, its potential effects on heart development

590 and function by regulating mitochondrial autophagy may influence cardiovascular  
591 disease risk<sup>41</sup>. Moreover, the *FTO* gene, located in the 16q12.2 region, is another gene  
592 of interest due to its impact on energy intake and expenditure, potentially increasing  
593 susceptibility to both MAFLD and CVDs<sup>42,43</sup>. Moreover, the *TRIB1* gene, located at  
594 8q24.13, plays a critical role in regulating lipid metabolism. It influences downstream  
595 signaling pathways such as PI3K-AKT and MAPK, which promote the accumulation  
596 of liver lipids and increase the risk of MAFLD<sup>44,45</sup>. Additionally, polymorphisms in  
597 the *TRIB1* gene have been linked to an increased risk of CAD and Stroke. Specifically,  
598 the A allele at rs2954029 has been significantly associated with these conditions;  
599 individuals carrying the A allele exhibit a higher risk of both CAD and stroke<sup>46</sup>.

600

601 Functional annotation via FUMA identified 24 intronic SNPs, 14 intergenic SNPs,  
602 and 5 exonic SNPs. For example, the 22q13.31 region includes the exonic SNP  
603 rs1007863, which showed significant eQTL associations in several tissues: adipose  
604 subcutaneous ( $P = 2.38 \times 10^{-6}$ ), adipose visceral omentum ( $P = 2.16 \times 10^{-15}$ ), whole  
605 blood ( $P = 3.57 \times 10^{-5}$ ), artery aorta ( $P = 3.57 \times 10^{-5}$ ), and artery tibial ( $P = 1.42 \times 10^{-12}$ ).  
606 Notably, the P-value for adipose visceral omentum was used as the P-value for this  
607 region in MAFLD-AF for PLACO results, indicating that this P-value is considered  
608 the most appropriate or representative indicator, suggesting that visceral tissues are  
609 importantly associated with this trait pair. Seven of all pleiotropic SNPs were  
610 identified as potentially deleterious, with a CADD score greater than 12.37. Notably,  
611 rs28929474 exhibited the highest CADD score of 20.2, suggesting its potential

612 association with the development of MAFLD and CAD and its deleterious effects.  
613 Furthermore, based on RDB scores, two SNPs were found to potentially impact  
614 transcription factor binding, with rs10401969 showing the most significant effect  
615 (RBD = 1f). Further colocalization analysis revealed evidence of colocalization in 13  
616 of the 49 pleiotropic loci (PPH4 > 0.7). Notably, the 16q12.2 region has demonstrated  
617 a robust colocalization signal across all four trait pairs it encompasses (with a  
618 posterior probability of heterogeneity, PPH4, ranging from 0.766 to 0.890).

619

#### 620 **Gene-level annotation of MAFLD and CVDs**

621 Using MAGMA, we identified 34 potential pleiotropic genes (28 of which are unique)  
622 between MAFLD and CVDs after Bonferroni correction, which is situated on or  
623 overlaps with 49 previously identified pleiotropic loci. Among these, 2 are novel  
624 unique genes, 3 have newly unique been associated with CVDs, and 23 are newly  
625 unique implicated in MAFLD. Notably, three genes—*SAMM50*, *PNPLA3*, and  
626 *FTO*—were detected in two or more trait pairs. Further, of the genes identified by  
627 MAGMA, 32 were corroborated by FUMA's locus mapping. The pervasive impact of  
628 *SAMM50* across multiple traits underscores its significance and makes it a primary  
629 focus of our ongoing investigation.

630

631 We performed tissue-specific analyses employing LDSC-SEG to identify the tissues  
632 associated with each disease. After adjusting for multiple comparisons using the FDR  
633 method, significant associations were observed solely with CVDs. Specifically, for AF,

634 the auricle and the left ventricle were identified as the primary tissues driving the  
635 condition, suggesting that functional changes in these areas may play a crucial role in  
636 its development and maintenance. Similarly, in CAD, the predominant tissues  
637 associated with the disease were located in arterial regions, including the aorta,  
638 coronary artery, and anterior tibial artery, with the anterior tibial artery demonstrating  
639 the most significant impact. Unfortunately, while MAFLD showed enrichment in the  
640 anterior cingulate cortex, cerebral cortex, and frontal cortex, these did not meet the  
641 significant threshold for correction. In all, after integrating the results of tissue  
642 enrichment analysis with tissues commonly implicated in clinical practice for these  
643 conditions, we finally selected 10 tissues for subsequent analysis.

644

645 Given the limitations of MAGMA, which assigns SNPs based solely on proximity to  
646 genes and may overlook the effects of distant gene regulation, we employed  
647 e-MAGMA to overcome these deficiencies. By integrating eQTL data from 10  
648 distinct tissues, e-MAGMA enabled us to identify 161 tissue-specific genes, including  
649 59 that were unique. Notably, *IRAK1BP1*, *ATP13A1*, *SAMM50* and *NME7* were  
650 identified in more than half of the trait pairs. *IRAK1BP1* exhibits high specificity to  
651 nine tissues except EBV-transformed lymphocytes and has not previously been  
652 associated with MAFLD or any CVDs. However, its involvement in inflammation  
653 suggests a potential role in these diseases. Our findings were further validated using  
654 FUMA's GTExV8 data through e-MAGMA, confirming the identification of 78  
655 tissue-specific genes, including *SAMM50* at 22q13.31. Subsequent TWAS analysis of

656 the original GWAS results was used to validate the EMAGMA analysis, and 300  
657 tissue-specific genes were identified as new genes for MAFLD and 185 as new genes  
658 for CVDs.

659

660 Finally, 17 pleiotropic genes (14 unique) were identified by MAGMA and e-MAGMA.  
661 *SAMM50* at 22q13.31 was the only gene that appeared in multiple trait pairs (except  
662 for MAFLD-PAD and MAFLD-Stroke), while other genes appeared only in single  
663 trait pairs.

664

#### 665 **Functional enrichment analysis of pleiotropic genes in MAFLD and CVDs**

666 Understanding how identified genes collectively fulfill specific biological functions  
667 through shared pathways enhances our ability to derive meaningful interpretations  
668 from genomic data. The tool ToppFun assists in mapping these genes to their  
669 respective enrichment pathways and biological processes, which can reveal the  
670 activity levels or enrichment of certain pathways. Notably, three pathways were  
671 significantly enriched: membrane organization, endoplasmic reticulum tubular  
672 network organization, and the establishment of protein localization to the membrane.  
673 Protein localization is critical in the accumulation of lipid droplets near mitochondria;  
674 it helps protect mitochondrial function by sequestering toxic lipids. This protective  
675 mechanism is crucial for managing lipid accumulation in the liver and other tissues,  
676 where excessive lipid buildup can lead to MAFLD and CVDs<sup>47,48</sup>. Proper protein  
677 localization, therefore, plays a pivotal role in mitigating lipid toxicity and maintaining

678 cellular balance, thereby reducing the risk of both MAFLD and CVD.

679

## 680 **Discussion**

681 This genome-wide pleiotropic association study offers compelling evidence of a

682 shared genetic architecture and mechanisms between MAFLD and six major CVDs.

683 We observed moderate to strong genome-wide genetic associations between MAFLD

684 and four CVDs—CAD, HF, PAD, and VTE—with notable genetic overlap in all but

685 the MAFLD-AF trait pair. MR analysis provided evidence of causal relationships for

686 two trait pairs, underscoring the presence of vertical pleiotropy. Additionally, at the

687 SNP level, our cross-trait analysis pinpointed 49 pleiotropic loci, 13 demonstrating

688 strong evidence of colocalization. Further analysis at the gene level through MAGMA

689 and e-MAGMA identified 45 (34 unique) significant position-specific pleiotropic

690 genes and 161 (59 unique) tissue-specific pleiotropic genes, including 17 overlapping

691 pleiotropic genes (14 unique because *SAMM50* was identified in 4 trait pairs).

692 Moreover, at the biological pathway level, protein localization to membrane signaling

693 pathways was identified as potentially pivotal in the co-pathogenesis of MAFLD and

694 CVD. These insights not only deepen our understanding of their intertwined genetic

695 etiology but also illuminate potential targets for therapeutic intervention and

696 preventive strategies.

697

698 In our study, bivariate LDSC revealed extensive positive genetic correlations between

699 MAFLD and six major CVDs, among which only four trait pairs (including



700 MAFLD-CAD, MAFLD-HF, MAFLD-PAD, and MAFLD-VTE) passed the  
701 Bonferroni correction. Further analysis using the GPA method demonstrated  
702 significant genetic overlap for all pairs except MAFLD with AF, underscoring the  
703 shared genetic underpinnings of these conditions. Interestingly, although no  
704 significant genome-wide genetic correlation was detected between MAFLD and  
705 stroke, substantial genetic overlap suggested the presence of complex genomic  
706 interactions, which was also confirmed by local genetic correlations of LAVA. In the  
707 MAFLD-stroke pair, we identified loci with mixed effect directions—two positively  
708 and three negatively correlated—suggesting that local mixed effects might underlie  
709 the non-significant genome-wide genetic correlation, potentially driven by a range of  
710 pleiotropic variants<sup>11</sup>. Additionally, despite the lack of a significant association  
711 between MAFLD and AF in both LDSC and GPA analyses, our bivariate LAVA under  
712 a loose threshold indicated a positive regional genetic correlation between the two.  
713 Overall, our findings confirm that MAFLD and CVDs share substantial heritability  
714 and genetic components, elucidating the genetic basis of their high comorbidity.

715

716 The shared genetic basis between MAFLD and CVD is primarily driven by horizontal  
717 and vertical pleiotropy (i.e., causal relationships). We employed the LHC-MR method  
718 to investigate potential causal links between MAFLD and 6 major CVDs. Our  
719 analysis revealed that genetically predicted MAFLD is causally associated with an  
720 increased risk of AF and PAD. These findings are consistent with prior  
721 epidemiological evidence. A meta-analysis confirmed an association between

722 MAFLD and an increased risk of AF<sup>49</sup>. Concurrently, a separate cohort study  
723 observed a high prevalence of PAD among MAFLD patients over 40 years old in the  
724 United States during a 13-year follow-up<sup>50</sup>. Conversely, we found no established  
725 causal relationship between MAFLD and HF or Stroke, nor was a reverse causal  
726 relationship between MAFLD and CVD supported. This contrasts with earlier MR  
727 analyses that reported a positive causal relationship between MAFLD and both HF<sup>15</sup>  
728 and CAD<sup>14</sup>, which suggested a 15% increase in CAD incidence per unit increase in  
729 MAFLD. These discrepancies may arise from limitations in previous studies, such as  
730 potential genetic confounders and smaller sample sizes, which could impact the  
731 reliability of the exposure-outcome relationship. LHC-MR analysis is particularly  
732 effective at generating potential causal effects by excluding confounding factors, even  
733 in the face of unmeasured confounding. Leveraging extensive sample data and  
734 advanced methodologies, our study provided more robust and reliable causal effect  
735 estimates. Our study only provides partial evidence for vertical pleiotropy, suggesting  
736 that the shared genetic basis between MAFLD and CVD is primarily driven by  
737 horizontal pleiotropy.

738

739 Horizontal pleiotropy analysis further elucidated the common genetic architecture  
740 between MAFLD and CVD by discovering pleiotropic variants and loci, pleiotropic  
741 genes, and biological pathways between the two. Further investigation through  
742 horizontal pleiotropy analysis has confirmed their extensive comorbidity, identifying  
743 widespread pleiotropic variants across several key loci, such as 22q13.31, 16q12.2,

744 and 8q24.13, which are prominently associated with more than half of the trait pairs  
745 analyzed. Notably, the locus at 16q12.2—associated with all trait pairs except  
746 MAFLD-CAD and MAFLD-Stroke—maps to the *FTO* gene. This gene plays a  
747 critical role in lipid metabolism by enhancing oxidative stress and increasing  
748 lipogenesis in hepatocytes, thereby exacerbating MAFLD progression<sup>51</sup>. Moreover,  
749 according to a meta-analysis of 10 observational studies (19,153 CVD cases and  
750 103,720 controls), variants in the *FTO* gene have been shown to significantly elevate  
751 CVD risk, independent of BMI and other conventional risk factors<sup>52</sup>. Moreover, in a  
752 large prospective longitudinal study of Type 2 diabetes (T2D) patients, variants in the  
753 *FTO* gene were also found to increase the risk of myocardial infarction and  
754 cardiovascular death by influencing a dyslipidemic phenotype typical of insulin  
755 resistance<sup>53</sup>. The above evidence suggests that the lipid metabolism process can be  
756 significantly changed by affecting the expression of the *FTO* gene, thereby improving  
757 MAFLD and reducing the risk of cardiovascular death.

758

759 In our gene-level analysis using MAGMA and e-MAGMA, we identified significant  
760 pleiotropic genes at the 22q13.31 locus, including patatin-like phospholipase-domain  
761 containing protein 3 (*PNPLA3*) and sorting and assembly machinery component 50  
762 (*SAMM50*). These genes play crucial roles in the comorbidity between MAFLD and  
763 CVDs. *PNPLA3*, which exhibits weak hydrolytic activity towards glycerolipids, has  
764 been linked to the development of MAFLD and CVDs, excluding PAD and Stroke.  
765 This gene is associated with a missense variant closely linked to triacylglycerol (TAG)

766 accumulation in the liver—a major genetic risk factor for steatotic liver diseases<sup>54,55</sup>.  
767 *PNPLA3* competitively displaces adipose triglyceride lipase (ATGL) from lipid  
768 droplets, reducing lipolytic activity and promoting the progression of MAFLD<sup>54</sup>.  
769 Intriguingly, a GWAS meta-analysis revealed that the *PNPLA3* G-allele rs738409  
770 offers modest protection against CAD by reducing triglyceride breakdown in the liver,  
771 thus affecting the secretion of very low-density lipoprotein particles and the  
772 development of atherosclerosis<sup>56</sup>. Additionally, our e-MAGMA analysis identified  
773 *SAMM50* at this locus as influencing most trait pairs. As an essential component of  
774 the Sorting and Assembly Machinery (SAM) complex on the outer mitochondrial  
775 membrane, *SAMM50* is vital for  $\beta$ -barrel protein biogenesis and interacts directly with  
776 the translocator of the outer mitochondrial membrane (TOM) complex<sup>41</sup>. It plays a  
777 significant role in fatty acid  $\beta$ -oxidation and, when deficient, can lead to intracellular  
778 lipid accumulation, exacerbating MAFLD<sup>40</sup>. Moreover, *SAMM50*'s involvement in  
779 mitochondrial dysfunction may impair the removal of reactive oxygen species (ROS),  
780 further contributing to the progression of MAFLD<sup>57</sup> and increasing susceptibility to  
781 HF by impairing mitochondrial function<sup>41</sup>. This mitochondrial pathway regulated by  
782 *SAMM50* offers a theoretical basis for the observed comorbidity between MAFLD  
783 and HF in our study, underscoring the potential for targeted therapies at this genetic  
784 locus.

785

786 In our pathway-level analysis, we discovered a crucial role for the gene *SAMM50* in  
787 mediating protein localization to membranes, a process integral to the pathogenesis of

788 MAFLD. This protein localization is especially important in how lipid droplets  
789 accumulate near mitochondria, which may protect mitochondrial function by  
790 sequestering toxic lipid species. Proteins that migrate to these lipid droplets at  
791 membrane contact sites are prime candidates for facilitating this protective  
792 mechanism<sup>47,48</sup>. In the liver, an excessive influx of lipids leads to the accumulation of  
793 triglyceride (TG)-rich lipid droplets, a hallmark of MAFLD<sup>47</sup>. Variations in genes  
794 associated with lipid droplet formation, such as PNPLA3, acting as both  
795 phospholipase and acyl transfer enzyme, is an important regulating factor for TG. It  
796 limits the activity of triglyceride hydrolases, leading to TG accumulation in the liver,  
797 thus predisposing to MAFLD<sup>58</sup>. Moreover, when lipid droplets amass in peripheral  
798 organs, the overflow of toxic lipids can contribute to CVDs. ATGL plays a pivotal role  
799 in this context by hydrolyzing TG within these droplets. It activates the  
800 PPAR $\alpha$ /peroxisome proliferator-activated receptor- $\gamma$  coactivator 1 (*PGC1*) complex in  
801 cardiomyocytes. A deficiency in cardiac ATGL leads to reduced *PGC1* expression,  
802 resulting in mitochondrial dysfunction and lipid accumulation, which can progress to  
803 HF<sup>59</sup>. In conclusion, the localization of contact site proteins related to lipid droplets is  
804 instrumental in preventing lipid overflow and safeguarding mitochondrial function.  
805 This mechanism significantly reduces the risk of both MAFLD and CVD by  
806 maintaining crucial cellular balances and interactions.

807

808 Our study has several limitations. First, our study population was confined to  
809 individuals of European ancestry, necessitating further research across other ethnic

810 groups to determine the universal applicability of our findings. Second, the datasets  
811 used for MAFLD and CVD included some cases with existing or potential co-morbid  
812 conditions, which may have biased our investigation of genetic overlap. Third, our  
813 analysis was limited to common genetic variants, highlighting the need for future  
814 studies to explore the impact of rare variants, which may also significantly influence  
815 the high comorbidity observed between MAFLD and CVD. Finally, while we  
816 reported some statistically significant findings, further investigation is required to  
817 assess their clinical relevance and implications.

818

819 In summary, our study demonstrates extensive genetic overlap, partial genetic  
820 correlation, and causal relationships between MAFLD and six major CVDs.  
821 Identification of the pleiotropic gene, *SAMM50*, at pleiotropic risk loci 22q13.31,  
822 shared between MAFLD and CVD, suggesting a common biological mechanism,  
823 namely the establishment of protein localization to the membrane, uncovering  
824 indications of shared genetic foundation for MAFLD and CVDs. This research  
825 enhances the shared genetic map of these diseases and offers new perspectives on  
826 preventing and treating their co-morbidities.

827

828 **Abbreviations**

829 AF (atrial fibrillation) ApoC3 (apolipoprotein C3) ATGL (adipose triglyceride lipase)  
830 CVDs (cardiovascular diseases) CAD (coronary artery disease ) CRP (C-Reactive  
831 Protein) CADD (Combined Annotation-Dependent Depletion) e-MAGMA  
832 (eQTL-informed MAGMA) eMERGE (Electronic Medical Records and Genomics)  
833 EstBB (Estonian Biobank) FUMA (Functional Mapping and Annotation) FDR (false  
834 discovery rate) GPA (Genetic Analysis incorporating Pleiotropy and Annotation)  
835 GWAS (genome-wide association studies)  $h^2_{SNP}$  (SNP-based heritability) HF (heart  
836 failure) HUNT (Health Study Nord-Trøndelag) HERMES (Heart Failure Molecular  
837 Epidemiology for Therapeutic Targets) IVW (Inverse Variance Weighting) IL-1  
838 (interleukin-1) LDSC (linkage disequilibrium score regression) LD (linkage  
839 disequilibrium) LDSC-SEG (LDSC applied to specifically expressed genes) LRT  
840 (likelihood ratio test) LAVA (Local Analysis of [co]Variant Annotation) LHC-MR  
841 (Latent Heritable Confounder Mendelian randomization) MAFLD (metabolic  
842 dysfunction-associated fatty liver disease) MR (Mendelian Randomization) MGI  
843 (Michigan Genome Initiative) MAF (minor allele frequency) MHC (major  
844 histocompatibility complex) MAGMA (Multi-marker Analysis of GenoMic  
845 Annotation) NAFLD (Non-alcoholic fatty liver disease) OR (odds ratios) PAD  
846 (peripheral artery disease) PLACO (Pleiotropic Analysis under a Composite Null  
847 Hypothesis) RDB (RegulomeDB) PP (posterior probabilities) *PNPLA3* (patatin-like  
848 phospholipase-domain containing protein 3) *PGC1* (PPAR $\alpha$ /peroxisome  
849 proliferator-activated receptor- $\gamma$  coactivator 1) ROS (reactive oxygen species) SNPs

850 (single nucleotide polymorphisms) *SAMM50* (sorting and assembly machinery  
851 component 50) SAM (Sorting and Assembly Machinery) TWAS (transcriptome-wide  
852 association study) ToppFun (ToppGene functional annotation tool) TFBS  
853 (transcription factor binding sites) T2D (Type 2 diabetes) TAG (triacylglycerol) TOM  
854 (translocator of the outer mitochondrial membrane) TG (triglyceride) UKB (UK  
855 Biobank) VTE (venous thromboembolism)

856

### 857 **Acknowledgements**

858 We would like to thank all GWAS authors who provided summary statistics for this  
859 study. We thank the Electronic Medical Records and Genomics (eMERGE) Network,  
860 the UK Biobank (UKB), the Estonian Biobank (EstBB), and the FinnGen Consortium  
861 for providing us with data on MAFLD, without whom this work would not have been  
862 possible. We would also like to thank the Health Study Nord-Trøndelag (HUNT),  
863 deCODE, Michigan Genome Initiative (MGI), DiscovEHR, UKB, and AFGen  
864 consortium for providing AF data; the CARDIoGRAMplusC4D and UKB consortium  
865 for providing CAD data; the deCODE for providing VTE data; the Heart Failure  
866 Molecular Epidemiology for Therapeutic Targets (HERMES) consortium for  
867 providing HF data; the Cardiovascular Disease Knowledge Portal (CVDKP) website  
868 for providing PAD data; and the GIGASTROKE consortium for providing stroke  
869 data.

870



871 **References**

- 872 [1] Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et  
873 al. A new definition for metabolic dysfunction-associated fatty liver disease: An  
874 international expert consensus statement. *J Hepatol* 2020; 73: 202-9.
- 875 [2] Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven Proposed  
876 Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology* 2020;  
877 158: 1999-2014.e1.
- 878 [3] Sanyal AJ, Castera L, Wong VW. Noninvasive Assessment of Liver Fibrosis in  
879 NAFLD. *Clin Gastroenterol Hepatol* 2023; 21: 2026-39.
- 880 [4] Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related  
881 mortality in non-alcoholic fatty liver disease. *J Hepatol* 2008; 49: 608-12.
- 882 [5] Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to  
883 cardiovascular disease. *Mol Metab* 2020; 42: 101092.
- 884 [6] Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, et al. NAFLD and  
885 cardiovascular diseases: a clinical review. *Clin Res Cardiol* 2021; 110: 921-37.
- 886 [7] Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver  
887 disease and risk of incident cardiovascular disease: A meta-analysis. *J Hepatol* 2016;  
888 65: 589-600.
- 889 [8] Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al.  
890 Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic  
891 steatohepatitis from cardiovascular disease. *Hepatology* 2015; 61: 506-14.
- 892 [9] Brouwers M, Simons N, Stehouwer CDA, Koek GH, Schaper NC, Isaacs A.

893 Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and  
894 Coronary Artery Disease. *Hepatol Commun* 2019; 3: 587-96.

895 [10]Fang Z, Jia S, Mou X, Li Z, Hu T, Tu Y, et al. Shared genetic architecture and  
896 causal relationship between liver and heart disease. *iScience* 2024; 27: 109431.

897 [11]Hindley G, Frei O, Shadrin AA, Cheng W, O'Connell KS, Icick R, et al. Charting  
898 the Landscape of Genetic Overlap Between Mental Disorders and Related Traits  
899 Beyond Genetic Correlation. *Am J Psychiatry* 2022; 179: 833-43.

900 [12]Perry BI, Bowker N, Burgess S, Wareham NJ, Upthegrove R, Jones PB, et al.  
901 Evidence for Shared Genetic Aetiology Between Schizophrenia, Cardiometabolic, and  
902 Inflammation-Related Traits: Genetic Correlation and Colocalization Analyses.  
903 *Schizophr Bull Open* 2022; 3: sgac001.

904 [13]Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy  
905 in Mendelian randomization studies. *Hum Mol Genet* 2018; 27: R195-r208.

906 [14]Ren Z, Simons P, Wesselius A, Stehouwer CDA, Brouwers M. Relationship  
907 between NAFLD and coronary artery disease: A Mendelian randomization study.  
908 *Hepatology* 2023; 77: 230-8.

909 [15]Peng H, Wang S, Wang M, Ye Y, Xue E, Chen X, et al. Nonalcoholic fatty liver  
910 disease and cardiovascular diseases: A Mendelian randomization study. *Metabolism*  
911 2022; 133: 155220.

912 [16]Ghodsian N, Abner E, Emdin CA, Gobeil É, Taba N, Haas ME, et al. Electronic  
913 health record-based genome-wide meta-analysis provides insights on the genetic  
914 architecture of non-alcoholic fatty liver disease. *Cell reports Medicine* 2021; 2:

915 100437.

916 [17]Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, et  
917 al. Biobank-driven genomic discovery yields new insight into atrial fibrillation  
918 biology. *Nature genetics* 2018; 50: 1234-9.

919 [18]Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, et al. Discovery  
920 and systematic characterization of risk variants and genes for coronary artery disease  
921 in over a million participants. *Nature genetics* 2022; 54: 1803-15.

922 [19]Ghouse J, Tragante V, Ahlberg G, Rand SA, Jespersen JB, Leinøe EB, et al.  
923 Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction  
924 equivalent to monogenic forms of venous thromboembolism. *Nature genetics* 2023;  
925 55: 399-409.

926 [20]Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, et al.  
927 Genome-wide association and Mendelian randomisation analysis provide insights into  
928 the pathogenesis of heart failure. *Nature communications* 2020; 11: 163.

929 [21]van Zuydam NR, Stiby A, Abdalla M, Austin E, Dahlström EH, McLachlan S, et  
930 al. Genome-Wide Association Study of Peripheral Artery Disease. *Circulation*  
931 *Genomic and precision medicine* 2021; 14: e002862.

932 [22]Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, et al. Stroke  
933 genetics informs drug discovery and risk prediction across ancestries. *Nature* 2022;  
934 611: 115-23.

935 [23]Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A  
936 global reference for human genetic variation. *Nature* 2015; 526: 68-74.

- 937 [24]Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al.  
938 LD Score regression distinguishes confounding from polygenicity in genome-wide  
939 association studies. *Nature genetics* 2015; 47: 291-5.
- 940 [25]Zhang Y, Qi G, Park JH, Chatterjee N. Estimation of complex effect-size  
941 distributions using summary-level statistics from genome-wide association studies  
942 across 32 complex traits. *Nature genetics* 2018; 50: 1318-26.
- 943 [26]Finucane HK, Reshef YA, Anttila V, Slowikowski K, Gusev A, Byrnes A, et al.  
944 Heritability enrichment of specifically expressed genes identifies disease-relevant  
945 tissues and cell types. *Nature genetics* 2018; 50: 621-9.
- 946 [27]Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis:  
947 multitissue gene regulation in humans. *Science (New York, NY)* 2015; 348: 648-60.
- 948 [28]Chung D, Yang C, Li C, Gelernter J, Zhao H. GPA: a statistical approach to  
949 prioritizing GWAS results by integrating pleiotropy and annotation. *PLoS genetics*  
950 2014; 10: e1004787.
- 951 [29]Werme J, van der Sluis S, Posthuma D, de Leeuw CA. An integrated framework  
952 for local genetic correlation analysis. *Nature genetics* 2022; 54: 274-82.
- 953 [30]Darrous L, Mounier N, Kutalik Z. Simultaneous estimation of bi-directional  
954 causal effects and heritable confounding from GWAS summary statistics. *Nature*  
955 *communications* 2021; 12: 7274.
- 956 [31]Ray D, Chatterjee N. A powerful method for pleiotropic analysis under composite  
957 null hypothesis identifies novel shared loci between Type 2 Diabetes and Prostate  
958 Cancer. *PLoS genetics* 2020; 16: e1009218.

- 959 [32]Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and  
960 annotation of genetic associations with FUMA. *Nature communications* 2017; 8:  
961 1826.
- 962 [33]Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general  
963 framework for estimating the relative pathogenicity of human genetic variants. *Nature*  
964 *genetics* 2014; 46: 310-5.
- 965 [34]Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al.  
966 Annotation of functional variation in personal genomes using RegulomeDB. *Genome*  
967 *research* 2012; 22: 1790-7.
- 968 [35]Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic  
969 variants from high-throughput sequencing data. *Nucleic acids research* 2010; 38:  
970 e164.
- 971 [36]de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set  
972 analysis of GWAS data. *PLoS computational biology* 2015; 11: e1004219.
- 973 [37]Gerring ZF, Mina-Vargas A, Gamazon ER, Derks EM. E-MAGMA: an  
974 eQTL-informed method to identify risk genes using genome-wide association study  
975 summary statistics. *Bioinformatics (Oxford, England)* 2021; 37: 2245-9.
- 976 [38]Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate  
977 causal variants by statistical fine-mapping. *Nature reviews Genetics* 2018; 19:  
978 491-504.
- 979 [39]Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list  
980 enrichment analysis and candidate gene prioritization. *Nucleic acids research* 2009;

- 981 37: W305-11.
- 982 [40]Li Z, Shen W, Wu G, Qin C, Zhang Y, Wang Y, et al. The role of SAMM50 in  
983 non-alcoholic fatty liver disease: from genetics to mechanisms. *FEBS Open Bio* 2021;  
984 11: 1893-906.
- 985 [41]Xu R, Kang L, Wei S, Yang C, Fu Y, Ding Z, et al. Samm50 Promotes  
986 Hypertrophy by Regulating Pink1-Dependent Mitophagy Signaling in Neonatal  
987 Cardiomyocytes. *Front Cardiovasc Med* 2021; 8: 748156.
- 988 [42]Patnaik D, Jena AB, Kerry RG, Duttaroy AK. In silico profiling of  
989 nonsynonymous SNPs of fat mass and obesity-associated gene: possible impacts on  
990 the treatment of non-alcoholic fatty liver disease. *Lipids Health Dis* 2023; 22: 17.
- 991 [43]Xu ZY, Jing X, Xiong XD. Emerging Role and Mechanism of the FTO Gene in  
992 Cardiovascular Diseases. *Biomolecules* 2023; 13.
- 993 [44]Bauer RC, Yenilmez BO, Rader DJ. Tribbles-1: a novel regulator of hepatic lipid  
994 metabolism in humans. *Biochem Soc Trans* 2015; 43: 1079-84.
- 995 [45]Zhang T, Tan P, Wang L, Jin N, Li Y, Zhang L, et al. RNALocate: a resource for  
996 RNA subcellular localizations. *Nucleic acids research* 2017; 45: D135-d8.
- 997 [46]Jiang J, Chen X, Li C, Du X, Zhou H. Polymorphisms of TRIB1 genes for  
998 coronary artery disease and stroke risk: A systematic review and meta-analysis. *Gene*  
999 2023; 880: 147613.
- 1000 [47]Krahmer N, Najafi B, Schueder F, Quagliarini F, Steger M, Seitz S, et al.  
1001 Organellar Proteomics and Phospho-Proteomics Reveal Subcellular Reorganization in  
1002 Diet-Induced Hepatic Steatosis. *Dev Cell* 2018; 47: 205-21.e7.

- 1003 [48]Nguyen TB, Louie SM, Daniele JR, Tran Q, Dillin A, Zoncu R, et al.  
1004 DGAT1-Dependent Lipid Droplet Biogenesis Protects Mitochondrial Function during  
1005 Starvation-Induced Autophagy. *Dev Cell* 2017; 42: 9-21.e5.
- 1006 [49]Alon L, Corica B, Raparelli V, Cangemi R, Basili S, Proietti M, et al. Risk of  
1007 cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic  
1008 review and meta-analysis. *Eur J Prev Cardiol* 2022; 29: 938-46.
- 1009 [50]Ciardullo S, Bianconi E, Cannistraci R, Parmeggiani P, Marone EM, Perseghin G.  
1010 Peripheral artery disease and all-cause and cardiovascular mortality in patients with  
1011 NAFLD. *J Endocrinol Invest* 2022; 45: 1547-53.
- 1012 [51]Guo J, Ren W, Li A, Ding Y, Guo W, Su D, et al. Fat mass and obesity-associated  
1013 gene enhances oxidative stress and lipogenesis in nonalcoholic fatty liver disease. *Dig*  
1014 *Dis Sci* 2013; 58: 1004-9.
- 1015 [52]Liu C, Mou S, Pan C. The FTO gene rs9939609 polymorphism predicts risk of  
1016 cardiovascular disease: a systematic review and meta-analysis. *PLoS One* 2013; 8:  
1017 e71901.
- 1018 [53]Doney AS, Dannfald J, Kimber CH, Donnelly LA, Pearson E, Morris AD, et al.  
1019 The FTO gene is associated with an atherogenic lipid profile and myocardial  
1020 infarction in patients with type 2 diabetes: a Genetics of Diabetes Audit and Research  
1021 Study in Tayside Scotland (Go-DARTS) study. *Circ Cardiovasc Genet* 2009; 2: 255-9.
- 1022 [54]Witzel HR, Schwittai IMG, Hartmann N, Mueller S, Schattenberg JM, Gong XM,  
1023 et al. PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with  
1024 ATGL. *Cells* 2022; 12.

1025 [55]Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3  
1026 protein isoform (I148M) associated with nonalcoholic fatty liver disease. *J Biol Chem*  
1027 2011; 286: 37085-93.

1028 [56]Simons N, Isaacs A, Koek GH, Kuč S, Schaper NC, Brouwers M. PNPLA3,  
1029 TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease. *Gastroenterology*  
1030 2017; 152: 912-3.

1031 [57]Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, et al.  
1032 Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and  
1033 PARVB genes are associated with development and progression of nonalcoholic fatty  
1034 liver disease in Japan. *Hum Genet* 2013; 132: 783-92.

1035 [58]Dai G, Liu P, Li X, Zhou X, He S. Association between PNPLA3 rs738409  
1036 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and  
1037 severity: A meta-analysis. *Medicine* 2019; 98: e14324.

1038 [59]Krahmer N, Farese RV, Jr., Walther TC. Balancing the fat: lipid droplets and  
1039 human disease. *EMBO Mol Med* 2013; 5: 973-83.

1040



**Table 1. Genetic Correlation and Genetic Overlap Estimations Between 6 Pairwise Traits<sup>a</sup>**

Trait pair	Genetic correlation			Genetic overlap			
	Genetic correlation (SE)	<i>P</i> value for LDSC	Intercept (SE)	<i>P</i> value for intercept	PM 11	PAR <sup>b</sup>	<i>P</i> value for GPA
MAFLD-AF	0.1381 (0.0891)	0.121	0.0080 (0.0053)	0.131	0.0000	0.0004	9.55×10 <sup>-2</sup>
MAFLD-CAD <sup>c,d</sup>	0.6266 (0.1375)	5.18×10 <sup>-6</sup>	0.0018 (0.0059)	0.760	0.0036	0.0424	7.12×10 <sup>-31</sup>
MAFLD-HF <sup>c,d</sup>	0.5725 (0.1576)	3.00×10 <sup>-4</sup>	0.0058 (0.0045)	0.197	0.0001	0.0010	1.12×10 <sup>-11</sup>
MAFLD-PAD <sup>c,d</sup>	0.6259 (0.2099)	2.90×10 <sup>-3</sup>	0.0075 (0.0053)	0.157	0.0001	0.0029	1.32×10 <sup>-03</sup>
MAFLD-Stroke <sup>d</sup>	0.2783 (0.1353)	3.98×10 <sup>-2</sup>	0.0057 (0.0045)	0.205	0.0001	0.0007	6.96×10 <sup>-6</sup>
MAFLD-VTE <sup>c,d</sup>	0.4844 (0.1220)	7.19×10 <sup>-5</sup>	0.0025 (0.0051)	0.624	0.0002	0.0025	4.66×10 <sup>-10</sup>

Note:

a. Genetic correlation and genetic overlap were estimated by LDSC and GPA methods, respectively. Bonferroni-corrected significance threshold was set at  $P \leq 8.33 \times 10^{-3}$  (0.05/6), producing a final union set of 5 pairwise traits with significant genetic correlation or genetic overlap for subsequent analysis.

b. We introduced PAR as  $PM_{11} / (PM_{10} + PM_{01} + PM_{11})$  to represent the proportion of pleiotropic single-nucleotide variations (SNPs) associated with both traits against the proportion of SNPs associated with at least 1 trait.

c. Pairwise trait with significant genetic correlation.

d. Pairwise trait with significant genetic overlap.

Abbreviations: MAFLD, Metabolic dysfunction-Associated fatty liver disease; AF, Atrial fibrillation; CAD, Coronary artery disease; HF, Heart failure; PAD, Peripheral artery disease; VTE, Venous thromboembolism; LDSC, linkage disequilibrium score regression; GPA, genetic analysis incorporating pleiotropy and annotation method; PAR, pleiotropy association ratio; PM 11, proportion of genetic variants associated with both traits.

## Figure legends

### **Figure 1. Metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases estimated by local genetic correlation.**

LAVA volcano plots showing local genetic correlation coefficients (local- $r_{gs}$ , y-axis) for MAFLD and CVDs with  $-\log_{10}$   $p$ -values for each trait pair of analyses for each locus. Loci above the horizontal line are significant at  $P < 0.05$  (negative correlation for blue dots, positive correlation for red dots). Larger points with black circles indicate loci significantly associated after Bonferroni correction ( $P = 6.49 \times 10^{-4} = 0.05 / 77$ ). LAVA-estimated local- $r_{gs}$  is shown on the blue-red scale. MAFLD, metabolic dysfunction-associated fatty liver disease; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

### **Figure 2. Inference of bidirectional causal relationship between metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases.**

Forest plots of the causal relationship between MAFLD and six major CVDs using the LHC-MR method. The estimates presented in the forest plot were obtained using the LHC-MR method. A positive association is indicated by the odd ratio (OR > 1), while a negative association is indicated by OR < 1. The results of forward causality from the LHC-MR method are in the up panel, and the results of reverse causality from the LHC-MR method are in the down panel. MAFLD, metabolic dysfunction-associated fatty liver disease; AF, atrial fibrillation; CAD, coronary artery

disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

**Figure 3. Manhattan plots for the PLACO results of metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases.**


Manhattan plots reflect chromosomal position (x-axis) and negative log<sub>10</sub>-transformed P-values (y-axis) for each SNP. The horizontal dashed red line indicates the genome-wide significant P-value of  $-\log_{10}(5 \times 10^{-8})$ . The  $r^2$  threshold for defining independent significant SNPs was set to 0.2, and the maximum distance between LD blocks merged into one locus was set to 500 kb. The independent genome-wide significant associations with the smallest P-value (Top lead SNP) are encircled in a colorful circle. Only SNPs shared across all summary statistics were included. MAFLD, metabolic dysfunction-associated fatty liver disease; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

**Figure 4. The overall situation of the pleiotropy association between metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases.**


A circular dendrogram showing the shared genes between MAFLD (center circle) and each of six CVDs (first circle), resulting in six pairs. A total of 49 shared loci were identified across six trait pairs (third circle), mapped to 45 nominally significant pleiotropic genes (34 were Bonferroni-corrected significant) identified by

multimarker analysis of GenoMic annotation (MAGMA). For the trait pairs with more than three pleiotropic genes, we only showed the top 3 pleiotropic genes according to the prioritization of candidate pleiotropic genes (fourth circle). MAFLD, metabolic dysfunction-associated fatty liver disease; AF, Atrial fibrillation; CAD, Coronary artery disease; VTE, Venous thromboembolism; HF, Heart failure; PAD, Peripheral artery disease.


**Figure 1.**



**Figure 2.**




**Figure 3.**









MAFLD-AF




MAFLD-CAD




MAFLD-VTE




MAFLD-HF



MAFLD-PAD










MAFLD-Stroke




rho












Metabolic dysfunction-associated fatty liver disease




Cardiovascular diseases




(a) Linkage disequilibrium score regression




(b) Genetic analysis incorporating Pleiotropy and Annotation



(c) Local Analysis of [co]Variant Annotation



(d) Latent Heritable Confounder MR



(e) Pleiotropic Analysis under a Composite Null Hypothesis